Diamyd Medical
8.21
SEK
+5.66 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+5.66%
+0.35%
-52.58%
-49.52%
-37.03%
-30.26%
-45.34%
-57.46%
+175.11%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.07B SEK
Turnover
3.65M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
25.6
2025
Interim report Q3'25
8.10
2025
Annual report '25
All
Press releases
ShowingAll content types
Diamyd Medical AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes
Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools